Complement activation is associated with more severe course of
diarrhea-associated hemolytic uremic syndrome, a preliminary
study

J 2018

Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

KARNISOVA, Lucia, Ondrej HRADSKY, Kveta BLAHOVA, Filip FENCL, Zdeněk DOLEŽEL et. al.

Basic information

Original name

Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study

Authors

KARNISOVA, Lucia (203 Czech Republic, guarantor), Ondrej HRADSKY (203 Czech Republic), Kveta BLAHOVA (203 Czech Republic), Filip FENCL (203 Czech Republic), Zdeněk DOLEŽEL (203 Czech Republic, belonging to the institution), Tomas ZAORAL (203 Czech Republic) and Jakub ZIEG (203 Czech Republic)

Edition

European journal of pediatrics, New York, Springer, 2018, 0340-6199

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30209 Paediatrics

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.188

RIV identification code

RIV/00216224:14110/18:00104709

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00431-018-3255-2

UT WoS

000450003400013

Keywords in English

Complement; Hemolytic uremic syndrome; Shiga toxin-producing Escherichia coli; Renal replacement therapy

Abstract

V originále

Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r=-0.62, p=0.0001) and the initial glomerular filtration rate (r=0.36, p=0.026). Patients with C3<0.825g/L needed renal replacement therapy and also had significantly more renal complications (p=0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome.

Citovat

KARNISOVA, Lucia, Ondrej HRADSKY, Kveta BLAHOVA, Filip FENCL, Zdeněk DOLEŽEL, Tomas ZAORAL and Jakub ZIEG. Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. European journal of pediatrics. New York: Springer, 2018, vol. 177, No 12, p. 1837-1844. ISSN 0340-6199. Available from: https://dx.doi.org/10.1007/s00431-018-3255-2.

@article{1473308,
   author = {Karnisova, Lucia and Hradsky, Ondrej and Blahova, Kveta and Fencl, Filip and Doležel, Zdeněk and Zaoral, Tomas and Zieg, Jakub},
   article_location = {New York},
   article_number = {12},
   doi = {http://dx.doi.org/10.1007/s00431-018-3255-2},
   keywords = {Complement; Hemolytic uremic syndrome; Shiga toxin-producing Escherichia coli; Renal replacement therapy},
   language = {eng},
   issn = {0340-6199},
   journal = {European journal of pediatrics},
   title = {Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study},
   volume = {177},
   year = {2018}
}

TY  - JOUR
ID  - 1473308
AU  - Karnisova, Lucia - Hradsky, Ondrej - Blahova, Kveta - Fencl, Filip - Doležel, Zdeněk - Zaoral, Tomas - Zieg, Jakub
PY  - 2018
TI  - Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study
JF  - European journal of pediatrics
VL  - 177
IS  - 12
SP  - 1837-1844
EP  - 1837-1844
PB  - Springer
SN  - 03406199
KW  - Complement
KW  - Hemolytic uremic syndrome
KW  - Shiga toxin-producing Escherichia coli
KW  - Renal replacement therapy
N2  - Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r=-0.62, p=0.0001) and the initial glomerular filtration rate (r=0.36, p=0.026). Patients with C3<0.825g/L needed renal replacement therapy and also had significantly more renal complications (p=0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome.
ER  -

KARNISOVA, Lucia, Ondrej HRADSKY, Kveta BLAHOVA, Filip FENCL, Zdeněk DOLEŽEL, Tomas ZAORAL and Jakub ZIEG. Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. \textit{European journal of pediatrics}. New York: Springer, 2018, vol.~177, No~12, p.~1837-1844. ISSN~0340-6199. Available from: https://dx.doi.org/10.1007/s00431-018-3255-2.

Detailed Information on Publication Record